Recap: On June 24, eXoZymes has been awarded a $2 million Phase IIB SBIR grant from the NIH to advance the development of rare cannabinoids and novel cannabinoid analogs for drug discovery. Over the next two years, the company will use its AI-enhanced, cell-free biomanufacturing platform to expand its library of proprietary molecules, optimize production, and generate preclinical data, further validating its technology while supporting future pharmaceutical partnership and licensing opportunities.
Full story available here on bionity.com